Hydration Support to Reduce Side Effects in Adults Starting GLP-1RA Therapy for Obesity and Type 2 Diabetes

What this Trial Is About

Researchers are evaluating a hydration intervention aimed at reducing side effects in adults starting GLP-1 receptor agonist GLP-1 RA therapy for obesity and type 2 diabetes. This 17-week pilot study includes a one-week run-in period followed by a 16-week intervention to explore whether increasing hydration can lessen the severity and amount of side effects and reduce drug discontinuation. The study focuses on feasibility, participant retention, feedback, and adherence to protocols. Participants are randomly assigned to either the Hydration Plus group or a control group. The Hydration Plus group receives coaching that includes goal setting, planning, coping strategies, positive feedback, and a payment schedule based on meeting hydration goals. The control group receives hydration information and prompts but no behavior change techniques. The study assesses hydration levels and side effects over the intervention period. Throughout the study, participants complete assessments including hydration biomarker measurements, physiological and perceived hydration level evaluations, and symptom tracking. Researchers also monitor body mass index BMI, extracellular and intracellular water changes, and side effect severity. The total participation lasts 17 weeks, with evaluations at baseline, during the run-in week, and at the end of the program to assess the interventions acceptability, feasibility, and preliminary impact.

Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy